This trial is conducted in Europe. The aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body), safety and tolerability of oral semaglutide (NNC0113-0217) in subjects with mild, moderate and severe degrees of hepatic impairment compared to subjects with normal hepatic function.

Inclusion Criteria:

• Subject with normal hepatic function or hepatic impairment (mild, moderate or severe)
• Body mass index (BMI) 18.5-40.0 kg/m^2 (both inclusive)

Exclusion Criteria:

• Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods
• History of Crohn's disease, ulcerative colitis, or other inflammatory bowel disease
• Uncontrolled hypertension (defined as systolic blood pressure above or equal to 180 mmHg and/or diastolic blood pressure above or equal to 100 mmHg)
• Any donation of blood or plasma in excess of 400 mL within the 3 months preceding screening
• History of significant drug abuse, or a positive drug test at the screening visit (Visit 2)